FTSE MIB
34.088,20 -63,21 (-0,19%) Dow Jones
39.056,39 +172,13 (+0,44%) Nasdaq
16.302,76 -29,80 (-0,18%) Nikkei 225
38.073,98 -128,39 (-0,34%) Petrolio
79,47 +0,48 (+0,61%) Bitcoin EUR
56.959,65 -1.054,53 (-1,82%)
BioRestorative Therapies, Inc. (BRTX)
Dopo ore:
| Chiusura precedente | 1,4700 |
| Aperto | 1,4300 |
| Denaro | 1,3800 x 200 |
| Lettera | 1,4300 x 400 |
| Min-Max giorno | 1,3699 - 1,4399 |
| Intervallo di 52 settimane | 1,2000 - 7,1300 |
| Volume | |
| Media Volume | 577.350 |
| Capitalizzazione | 9,613M |
| Beta (5 anni mensile) | 61,53 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,4200 |
| Prossima data utili | 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,50 |
GlobeNewswireBioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference. Company BioRestorative Therapies, Inc.Presenter Lance Alstodt, Chief Executive OfficerDate & Time Thursday October 12th, 9:00am estLocation Yale Club, 50 Vanderbilt Avenue, NYC
- GlobeNewswire
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
--BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement --Agreement Represents Initial Venture into the $62.8 Billion Global Aesthetics Market --Initial Order of 5,000 Vials of Product Represents Controlled Launch and Will Have Positive Financial Impact MELVILLE, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a cl
- GlobeNewswire
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New York State's largest health care provider, has been activated and can
